| (Values in U.S. Thousands) | Dec, 2024 | Jun, 2024 | Dec, 2023 | Jun, 2023 | Dec, 2022 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Iq-Ai Limited (IQAI.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on proven technologies. Its geographical segment includes Jersey and the United States of America and reportable segments are holding company expenses and medical software. The company derives a majority of revenue from the United States of America. It also supplies medical technology solutions and has a strong neuroimaging product portfolio.